IMCR vs UFPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.
UFPT exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very conservative debt profile. However, the stock is currently trading at a significant premium, with a current price of $198.68 well above its Graham Number ($104.01) and Intrinsic Value ($150.50). While the earnings track record is stellar, organic growth is sluggish at 1.5%, and high customer concentration (45.8% from two clients) presents a systemic risk. The combination of a high PEG ratio (3.80) and bearish insider activity suggests the stock is currently overvalued despite its operational excellence.
Compare Another Pair
Related Comparisons
IMCR vs UFPT: Head-to-Head Comparison
This page compares Immunocore Holdings plc (IMCR) and UFP Technologies, Inc. (UFPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.